EGFR and neoplasm: In colorectal ‘xenospheres’ treated with cetuximab, CAF-produced HGF significantly protected colon cancer stem-like cells from the effect of the drug, by preserving cell viability and inhibiting apoptosis; in vivo, the concomitant inhibition of EGFR and MET resulted in a more pronounced tumor regression compared to cetuximab monotherapy [67].